Results
eNauka >
Results >
CELSG CML 11 "ISTAHIT" Phase III Study - Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL(+) CML Patients in Chronic Phase
| Title: | CELSG CML 11 "ISTAHIT" Phase III Study - Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL(+) CML Patients in Chronic Phase | Authors: | Petzer, Andreas L.; Wolf, Dominik; Fong, Dominic; Bošković, Darinka; Ulmer, Hanno; Gastl, Guenther | Issue Date: | 2008 | Publication: | Blood | ISSN: | 0006-4971 Blood Search Idenfier |
Publisher: | Orlando, FL, etc. : Grune and Stratton. | Type: | Conference Paper | Collation: | vol. 112 br. issue 11 str. 406-406 | WoS-ID: | 000262104701336 | VBS COBISS: | 1024773813 | URI: | https://plus.cobiss.net/cobiss/sr/sr/bib/1024773813#izum.si https://enauka.gov.rs/handle/123456789/646466 |
M-category: | Mp. category will be shown later |
Google ScholarTM
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.